Literature DB >> 3621224

Treatment of metastatic malignant melanoma with dacarbazine and cisplatin.

R Oratz, J L Speyer, M Green, R Blum, J C Wernz, F M Muggia.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3621224

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


× No keyword cloud information.
  5 in total

Review 1.  Systemic chemotherapy for malignant melanoma.

Authors:  A S Coates
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

2.  Phase II trial of carboplatin in patients with advanced melanoma.

Authors:  E S Casper; D Bajorin
Journal:  Invest New Drugs       Date:  1990-05       Impact factor: 3.850

3.  Carboplatinum and cytosine arabinoside in patients with disseminated malignant melanoma. A phase II study.

Authors:  B Jeremic; L Djuric; L Mijatovic
Journal:  Invest New Drugs       Date:  1991-08       Impact factor: 3.850

4.  A phase II study of combined administration of dacarbazine and carboplatin with home therapy of recombinant interleukin-2 and interferon-alpha 2a in patients with advanced malignant melanoma.

Authors:  I G Ron; Y Mordish; A Eisenthal; Y Skornick; M J Inbar; S Chaitchik
Journal:  Cancer Immunol Immunother       Date:  1994-06       Impact factor: 6.968

5.  Treatment of metastatic malignant melanoma with dacarbazine, vindesine and cisplatin.

Authors:  D Pectasides; H Yianniotis; N Alevizakos; D Bafaloukos; V Barbounis; J Varthalitis; M Dimitriadis; A Athanassiou
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.